Phlox Therapeutics is developing Ribonucleic acid (RNA)-based gene therapies to treat cardiomyopathies, disorders that affect the heart muscle.
Phlox Therapeutics has raised €1.9M across 1 funding round from 5 investors, most recently a round in Nov 2024. Based in Naarden, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-11-13 | Other | €1.9M |
| Amsterdam UMC Venture Holding,FIRST Fund,ROM Utrecht Region,syndicate,Utrecht Health Seed Fund (UHSF) |
| View deal → |
